PRL offers good results for high myopia

Article

Implantation of phakic refractive lenses (PRL) appears to be a predictable and well-tolerated procedure for correcting high myopia.

Implantation of phakic refractive lenses (PRL) appears to be a predictable and well-tolerated procedure for correcting high myopia, according to Esther Arranz-Marquez and co-workers from Vissum Corporación Oftalmológica de Madrid, Spain.

In a prospective study, the PRL was implanted in 78 myopic eyes in which the refractive error ranged between -4.0 and -31.0 D and laser refractive surgery was contraindicated. Uncorrected and best corrected visual acuity (UCVA & BCVA), manifest and cycloplegic refractions and intraocular pressure (IOP) were assessed over a three-year follow-up period.

The results revealed a significant change in spherical equivalent from a preoperative mean value of -14.7±5.4 D to 0±0.8 D three years postoperatively (p<0.01). UCVA and BCVA also improved significantly (p<0.01). Although a significant increase in IOP was found at each postoperative visit (p<0.01), there was no significant difference in IOP between one and three years postoperatively. Four eyes were operated on again due to mild lens decentration.

It was concluded that implantation of a PRL can offer good and predictable results for the correction of high myopia.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.